the failure of this study to prolong survival by using alternating regimens may be due to ( a ) the likely possibility that the initial two regimens are not actually non-cross-resistant in most myeloma patients , and ( b ) the long interval between the alternating regimens , particularly in the face of the low response rate to the initial regimen of melphalan and prednisone .
C0026764
myeloma
C0025241
melphalan